barchart.com
Crohn's Disease Clinical Trials And Studies 2025: EMA, PDMA, FDA Approvals, Mechanism ...
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on biologics or considering clinical trials may find candidates and study targets named here.
Adult patients with Crohn’s disease, people on biologic or targeted therapies, clinicians following emerging treatments, and researchers tracking the Crohn’s pipeline.
What To Know
This article summarizes a DelveInsight pipeline report and press-release style highlights about Crohn’s disease clinical development in 2025.
It lists many companies and pipeline candidates, and calls out recent or ongoing studies including guselkumab (phase 3 for fistulizing/perianal disease), RO7790121 (RVT-3101) phase 2, TRX103 phase 1/2a, and other trials and pipeline therapies such as etrasimod, infliximab, risankizumab, CT-P13 and filgotinib.
The piece appears to be an industry/pipeline roundup rather than a clinical guideline or new trial result; it mainly aggregates company names, trial intents, and drug candidates from a commercial report. It does not present patient-level outcomes or new efficacy/safety data.
If you want more detail, the original DelveInsight report and the clinical trial registrations referenced would be the primary sources for full protocols, eligibility, and results when available.
This is a press-style summary of a commercial pipeline report (DelveInsight) and mentions planned or ongoing trials rather than published trial results. It should not be taken as evidence of benefit or safety — consult trial registries or primary study reports for details.
